Demarchi L M, Reis M M, Palomino S A, Farhat C, Takagaki T Y, Beyruti R, Saldiva P H, Capelozzi V L
Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Mod Pathol. 2000 May;13(5):511-20. doi: 10.1038/modpathol.3880089.
Data from 64 patients who underwent surgical resection of lung adenocarcinomas were studied to identify clinicopathologic markers that might provide prognostic information on the clinical behavior of this neoplasia Patient staging was performed in accordance with the tumor-node-metastasis system as follows: Stage I (n = 29), Stage II (n = 11), Stage IIIA (n = 21), and Stage IIIB (n = 3). Overall follow-up time corresponded to the follow-up time for patients who were alive and to the survival time for patients who had died, all of them expressed in months. Data included age, staging, histologic type, morphometric assessment of histologic features related to tumor (stroma and vascularization), and immunohistochemical detection of proliferation cell markers (Ki-67 protein and proliferating cell nuclear antigen) and p53 protein. The morphometric assessment was made by the point-counting procedure. Data analysis included Life Tables for Survival and Cox Regression models. Overall follow-up analysis showed that significant univariate predictors (P < .05) were T stage; N stage; tumor stromal proportion; and immunohistochemical indexes of proliferating cell nuclear antigen, Ki-67, and p53 proteins. Variables that presented independent predictive value for overall follow-up with the multivariate model (P < .05) were sex, T stage, N stage, tumor stromal proportion, and immunohistochemical detection of p53 protein. We conclude that tumor stromal proportion and immunohistochemical detection of p53 protein, controlled for sex, T stage, and N stage, may be of critical value in the evaluation of recurrence of lung adenocarcinoma, serving as indicators for a more accurate prognosis.
对64例行肺腺癌手术切除患者的数据进行研究,以确定可能为该肿瘤临床行为提供预后信息的临床病理标志物。患者分期按照肿瘤-淋巴结-转移系统进行,如下:I期(n = 29),II期(n = 11),IIIA期(n = 21),IIIB期(n = 3)。总体随访时间对应于存活患者的随访时间以及死亡患者的生存时间,均以月为单位表示。数据包括年龄、分期、组织学类型、与肿瘤相关的组织学特征(间质和血管形成)的形态计量评估,以及增殖细胞标志物(Ki-67蛋白和增殖细胞核抗原)和p53蛋白的免疫组化检测。形态计量评估采用点计数法进行。数据分析包括生存寿命表和Cox回归模型。总体随访分析显示,单因素显著预测指标(P < 0.05)为T分期、N分期、肿瘤间质比例以及增殖细胞核抗原、Ki-67和p53蛋白的免疫组化指标。多因素模型中对总体随访具有独立预测价值的变量(P < 0.05)为性别、T分期、N分期、肿瘤间质比例以及p53蛋白的免疫组化检测。我们得出结论,在控制性别、T分期和N分期的情况下,肿瘤间质比例和p53蛋白的免疫组化检测可能对评估肺腺癌复发具有关键价值,可作为更准确预后的指标。